ES2839211T3 - Método para purificar proteínas de fusión a albúmina - Google Patents

Método para purificar proteínas de fusión a albúmina Download PDF

Info

Publication number
ES2839211T3
ES2839211T3 ES16762595T ES16762595T ES2839211T3 ES 2839211 T3 ES2839211 T3 ES 2839211T3 ES 16762595 T ES16762595 T ES 16762595T ES 16762595 T ES16762595 T ES 16762595T ES 2839211 T3 ES2839211 T3 ES 2839211T3
Authority
ES
Spain
Prior art keywords
sequence
comprises seq
loop
seq
loop comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16762595T
Other languages
English (en)
Spanish (es)
Inventor
Timothy Pabst
Mariko Fonseca
Christopher Thompson
Alan Hunter
Xiangyang Wang
Liu Tie
Yiming Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Application granted granted Critical
Publication of ES2839211T3 publication Critical patent/ES2839211T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16762595T 2015-03-12 2016-03-11 Método para purificar proteínas de fusión a albúmina Active ES2839211T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562132198P 2015-03-12 2015-03-12
PCT/US2016/022003 WO2016145307A1 (en) 2015-03-12 2016-03-11 Method of purifying albumin-fusion proteins

Publications (1)

Publication Number Publication Date
ES2839211T3 true ES2839211T3 (es) 2021-07-05

Family

ID=56878920

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16762595T Active ES2839211T3 (es) 2015-03-12 2016-03-11 Método para purificar proteínas de fusión a albúmina

Country Status (10)

Country Link
US (3) US10683340B2 (https=)
EP (2) EP3842451A1 (https=)
JP (3) JP6862348B2 (https=)
KR (2) KR20170124592A (https=)
CN (1) CN107428817B (https=)
AU (4) AU2016228806B2 (https=)
CA (2) CA2977675A1 (https=)
ES (1) ES2839211T3 (https=)
IL (1) IL253971B (https=)
WO (1) WO2016145307A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012323316B2 (en) 2011-10-11 2017-08-10 Viela Bio, Inc. CD40L-specific Tn3-derived scaffolds and methods of use thereof
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
CA3115341A1 (en) 2018-05-16 2019-11-21 Lib Therapeutics, Llc Compositions comprising pcsk9-binding molecules and methods of use
BR112021008797A2 (pt) * 2018-11-09 2021-08-31 Neopep Pharma Gmbh & Co. Kg Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame
EP3711772A1 (en) * 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
CN110295152A (zh) * 2019-07-29 2019-10-01 北京泓恩生物科技有限公司 一种重组产朊假丝酵母尿酸酶的纯化方法
US11180540B2 (en) * 2019-12-06 2021-11-23 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
CN115996940A (zh) * 2020-07-01 2023-04-21 免疫医疗有限责任公司 用于纯化生物治疗剂的洗涤剂和方法
CN112062833A (zh) * 2020-10-09 2020-12-11 国药集团武汉血液制品有限公司 一种从血浆组分ⅳ沉淀中提取人血白蛋白的方法
CN115677848A (zh) * 2022-10-24 2023-02-03 通化安睿特生物制药股份有限公司 一种制备高纯度高稳定性蛋白质的方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007657A1 (en) 1999-07-27 2001-02-01 Phylos, Inc. Peptide acceptor ligation methods
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
ES2078518T3 (es) 1990-04-05 1995-12-16 Roberto Crea Mutagenesis por desplazamiento completo.
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE69935248T2 (de) 1998-12-02 2007-11-08 Adnexus Therapeutics, Inc., Waltham Dna-protein fusionen sowie anwendungen derselben
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
US6951725B2 (en) 2001-06-21 2005-10-04 Compound Therapeutics, Inc. In vitro protein interaction detection systems
KR100524872B1 (ko) 2003-12-04 2005-11-01 씨제이 주식회사 인터페론 베타의 정제방법
JP4939410B2 (ja) 2004-07-06 2012-05-23 バイオレン，インク． 強化された特性を持つ変性ポリペプチドを発生させるためのルックスルー変異誘発
EP1976876A4 (en) 2005-12-22 2010-01-13 Conjuchem Biotechnologies Inc PROCESS FOR PRODUCING PREFORMED ALBUMIN CONJUGATES AND THERAPEUTIC AGENT
CN102014888A (zh) 2007-07-03 2011-04-13 达努塔·克鲁谢夫斯卡 α-酮戊二酸的新医药用途
US20090176654A1 (en) 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
EP2215246B1 (en) 2007-10-31 2015-01-07 MedImmune, LLC Protein scaffolds
BRPI0919881B1 (pt) 2008-10-31 2021-09-08 Centocor Ortho Biotech Inc Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
BRPI1008532B1 (pt) 2009-02-12 2021-12-14 Janssen Biotech, Inc Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos
DK2427486T3 (en) * 2009-05-07 2015-05-26 Novozymes Biopharma Dk As A process for purifying albumin
CA2776241A1 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
CA2789337A1 (en) 2010-02-16 2011-08-25 Medimmune, Llc Hsa-related compositions and methods of use
CA2795325A1 (en) 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
CN103379915A (zh) 2011-02-15 2013-10-30 米迪缪尼有限公司 Hsa相关组合物及使用方法
AU2012323316B2 (en) * 2011-10-11 2017-08-10 Viela Bio, Inc. CD40L-specific Tn3-derived scaffolds and methods of use thereof
MX2015005363A (es) * 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.

Also Published As

Publication number Publication date
WO2016145307A1 (en) 2016-09-15
IL253971A0 (en) 2017-10-31
IL253971B (en) 2021-10-31
AU2021200423A1 (en) 2021-02-25
JP2023103368A (ja) 2023-07-26
CN107428817B (zh) 2022-07-12
AU2023204271A1 (en) 2023-07-27
JP2018513124A (ja) 2018-05-24
CN107428817A (zh) 2017-12-01
KR20240093725A (ko) 2024-06-24
AU2026201911A1 (en) 2026-04-02
AU2016228806B2 (en) 2020-10-22
AU2016228806A1 (en) 2017-08-31
US20180105575A1 (en) 2018-04-19
JP7826243B2 (ja) 2026-03-09
CA2977675A1 (en) 2016-09-15
JP7320550B2 (ja) 2023-08-03
JP2021105025A (ja) 2021-07-26
US20230340074A1 (en) 2023-10-26
EP3268389A4 (en) 2018-08-08
AU2023204271B2 (en) 2026-04-02
BR112017019401A2 (pt) 2018-05-02
JP6862348B2 (ja) 2021-04-21
CA3260163A1 (en) 2026-03-02
KR20170124592A (ko) 2017-11-10
EP3268389A1 (en) 2018-01-17
EP3268389B1 (en) 2020-09-30
US11548933B2 (en) 2023-01-10
EP3842451A1 (en) 2021-06-30
AU2021200423B2 (en) 2023-04-06
US20200407423A1 (en) 2020-12-31
US10683340B2 (en) 2020-06-16

Similar Documents

Publication Publication Date Title
ES2839211T3 (es) Método para purificar proteínas de fusión a albúmina
CA3059994C (en) Human coagulation factor ix (fix) fusion protein, preparation method therefor, and use thereof
CN110234355B (zh) 单体人IgG1 Fc和双特异性抗体
KR20210149779A (ko) Fc 영역 개변 항체의 정제 방법
JP6352354B2 (ja) 非ペプチドヒンジ部含有フレキシブル抗体様分子
JP2024539653A (ja) 生体液を精製するための組成物及び方法
KR20250148832A (ko) 알부민 융합 단백질의 정제방법
CN112969477B (zh) 改善肽的血液动力学的方法
HK1245286B (en) Method of purifying albumin-fusion proteins
BR112017019401B1 (pt) Método de purificação de proteínas de fusão de albumina
WO2023133594A2 (en) Stabilized single immunoglobulin variable domains
HK40090436A (zh) Cd40l-特异性tn3-衍生的支架及其使用方法
HK40027581B (zh) 从宿主细胞半乳糖凝集素和其他污染物中纯化糖基化蛋白的方法